Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients at least 18 years of age at Visit 1
Drug naïve patients with T2DM diagnosed at least 2 months prior to Visit 1
HbA1c ≥ 7.0 % and ≤ 10.0% at Visit 1
Body Mass Index (BMI) in the range of 22-45 kg/m2 at Visit 1
Pregnant or lactating female
FPG ≥ 270 mg/dL (≥15 mmol/L)
Other protocol-defined inclusion/exclusion criteria may apply